Annual Accounts Receivable
$358.00 M
-$534.00 M-59.87%
December 31, 2024
Summary
- As of February 20, 2025, MRNA annual accounts receivable is $358.00 million, with the most recent change of -$534.00 million (-59.87%) on December 31, 2024.
- During the last 3 years, MRNA annual accounts receivable has fallen by -$2.82 billion (-88.72%).
- MRNA annual accounts receivable is now -88.72% below its all-time high of $3.17 billion, reached on December 31, 2021.
Performance
MRNA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$358.00 M
-$1.21 B-77.11%
December 31, 2024
Summary
- As of February 20, 2025, MRNA quarterly accounts receivable is $358.00 million, with the most recent change of -$1.21 billion (-77.11%) on December 31, 2024.
- Over the past year, MRNA quarterly accounts receivable has dropped by -$534.00 million (-59.87%).
- MRNA quarterly accounts receivable is now -88.88% below its all-time high of $3.22 billion, reached on March 31, 2021.
Performance
MRNA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
MRNA Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -59.9% | -59.9% |
| 3 y3 years | -88.7% | -59.9% |
| 5 y5 years | +3683.6% | -59.9% |
MRNA Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -88.7% | at low | -88.7% | +161.3% |
| 5 y | 5-year | -88.7% | +3683.6% | -88.9% | +3683.6% |
| alltime | all time | -88.7% | -100.0% | -88.9% | -100.0% |
Moderna Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $358.00 M(-59.9%) | $358.00 M(-77.1%) |
| Sep 2024 | - | $1.56 B(+859.5%) |
| Jun 2024 | - | $163.00 M(+19.0%) |
| Mar 2024 | - | $137.00 M(-84.6%) |
| Dec 2023 | $892.00 M(-35.6%) | $892.00 M(-52.2%) |
| Sep 2023 | - | $1.87 B(+704.3%) |
| Jun 2023 | - | $232.00 M(-79.2%) |
| Mar 2023 | - | $1.11 B(-19.6%) |
| Dec 2022 | $1.39 B(-56.4%) | $1.39 B(-48.6%) |
| Sep 2022 | - | $2.69 B(+0.1%) |
| Jun 2022 | - | $2.69 B(-15.2%) |
| Mar 2022 | - | $3.17 B(-0.1%) |
| Dec 2021 | $3.17 B(+128.3%) | $3.17 B(+1.1%) |
| Sep 2021 | - | $3.14 B(+55.5%) |
| Jun 2021 | - | $2.02 B(-37.3%) |
| Mar 2021 | - | $3.22 B(+131.5%) |
| Dec 2020 | $1.39 B(>+9900.0%) | $1.39 B(+583.7%) |
| Sep 2020 | - | $203.44 M(+304.1%) |
| Jun 2020 | - | $50.34 M(+379.6%) |
| Mar 2020 | - | $10.50 M(+10.9%) |
| Dec 2019 | $9.46 M(-58.3%) | $9.46 M(-47.8%) |
| Sep 2019 | - | $18.12 M(+67.3%) |
| Jun 2019 | - | $10.83 M(-39.7%) |
| Mar 2019 | - | $17.95 M(-20.8%) |
| Dec 2018 | $22.67 M(+49.5%) | $22.67 M(+96.2%) |
| Sep 2018 | - | $11.56 M(-23.8%) |
| Dec 2017 | $15.16 M(+12.1%) | $15.16 M(>+9900.0%) |
| Dec 2016 | $13.52 M(+2604.6%) | - |
| Sep 2015 | - | $0.00(0.0%) |
| Jun 2015 | - | $0.00(0.0%) |
| Mar 2015 | - | $0.00(-100.0%) |
| Dec 2014 | $500.00 K(+9900.0%) | $500.00 K(>+9900.0%) |
| Sep 2014 | - | $0.00(0.0%) |
| Jun 2014 | - | $0.00(0.0%) |
| Mar 2014 | - | $0.00(-100.0%) |
| Dec 2013 | $5000.00(-28.6%) | $5000.00(0.0%) |
| Sep 2013 | - | $5000.00(0.0%) |
| Jun 2013 | - | $5000.00(0.0%) |
| Mar 2013 | - | $5000.00(-28.6%) |
| Dec 2012 | $7000.00 | $7000.00(-97.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2012 | - | $250.00 K(>+9900.0%) |
| Dec 2011 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2011 | - | $10.00 K(+100.0%) |
| Jun 2011 | - | $5000.00(>+9900.0%) |
| Mar 2011 | - | $0.00(-100.0%) |
| Dec 2010 | $59.00 K(-72.0%) | $59.00 K(-72.0%) |
| Sep 2010 | - | $211.00 K(+91.8%) |
| Jun 2010 | - | $110.00 K(-13.4%) |
| Mar 2010 | - | $127.00 K(-39.8%) |
| Dec 2009 | $211.00 K(+559.4%) | $211.00 K(+330.6%) |
| Sep 2009 | - | $49.00 K(-18.3%) |
| Jun 2009 | - | $60.00 K(+361.5%) |
| Mar 2009 | - | $13.00 K(-59.4%) |
| Dec 2008 | $32.00 K(-90.1%) | $32.00 K(-91.7%) |
| Jun 2008 | - | $385.00 K(+9.1%) |
| Mar 2008 | - | $353.00 K(+9.0%) |
| Dec 2007 | $324.00 K(-88.4%) | $324.00 K(+161.3%) |
| Sep 2007 | - | $124.00 K(-65.6%) |
| Jun 2007 | - | $360.00 K(-55.9%) |
| Mar 2007 | - | $816.00 K(-70.8%) |
| Dec 2006 | $2.80 M(+1380.4%) | $2.80 M(+8.1%) |
| Sep 2006 | - | $2.59 M(+100.9%) |
| Jun 2006 | - | $1.29 M(-16.7%) |
| Mar 2006 | - | $1.55 M(+719.0%) |
| Dec 2005 | $189.00 K(+112.4%) | $189.00 K(-67.5%) |
| Sep 2005 | - | $582.00 K(-34.5%) |
| Jun 2005 | - | $888.00 K(+7.6%) |
| Mar 2005 | - | $825.00 K(-83.8%) |
| Sep 2004 | - | $5.09 M(+4487.4%) |
| Mar 2004 | - | $111.00 K(+24.7%) |
| Dec 2003 | $89.00 K(-88.1%) | $89.00 K(+345.0%) |
| Sep 2003 | - | $20.00 K(-62.3%) |
| Jun 2003 | - | $53.00 K(-89.0%) |
| Mar 2003 | - | $483.00 K(-35.2%) |
| Dec 2002 | $745.00 K(+949.3%) | $745.00 K(+709.8%) |
| Jun 2002 | - | $92.00 K(+26.0%) |
| Mar 2002 | - | $73.00 K(+2.8%) |
| Dec 2001 | $71.00 K | $71.00 K(-18.4%) |
| Sep 2001 | - | $87.00 K(+1.2%) |
| Jun 2001 | - | $86.00 K(+132.4%) |
| Mar 2001 | - | $37.00 K |
FAQ
- What is Moderna annual accounts receivable?
- What is the all time high annual accounts receivable for Moderna?
- What is Moderna annual accounts receivable year-on-year change?
- What is Moderna quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Moderna?
- What is Moderna quarterly accounts receivable year-on-year change?
What is Moderna annual accounts receivable?
The current annual accounts receivable of MRNA is $358.00 M
What is the all time high annual accounts receivable for Moderna?
Moderna all-time high annual accounts receivable is $3.17 B
What is Moderna annual accounts receivable year-on-year change?
Over the past year, MRNA annual accounts receivable has changed by -$534.00 M (-59.87%)
What is Moderna quarterly accounts receivable?
The current quarterly accounts receivable of MRNA is $358.00 M
What is the all time high quarterly accounts receivable for Moderna?
Moderna all-time high quarterly accounts receivable is $3.22 B
What is Moderna quarterly accounts receivable year-on-year change?
Over the past year, MRNA quarterly accounts receivable has changed by -$534.00 M (-59.87%)